Subscribe
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Best Practices in Breast Cancer Therapy | OFS
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Articles
Intermittent Androgen Suppression Recommended as New Standard in Recurrent Prostate Cancer
TON - Daily
Christin Melton
Data from a study presented at the 2011 Genitourinary Cancers Symposium supports the growing consensus that intermittent androgen suppression is no less effective than continuous androgen suppression at treating men with prostate cancer that recurs after radiotherapy. According to lead investigator Laurence Klotz, MD, chief of urology, Sunnybrook Health Sciences Centre, and professor of surgery at the University of Toronto, "Intermittent androgen suppression should be the standard of care for most patients with prostate-specific antigen [PSA] recurrence after radiation therapy" regardless of whether they have had radical prostatectomy.
The phase III trial enrolled 1386 men with nonmetastatic prostate cancer who experienced rising PSA and testoerone levels 1 year after radiotherapy, suggesting recurrence. Patients were randomized to receive androgen deprivation therapy (ADT) with a luteinizing hormone-releasing hormone (LHRH) continuously until they developed resistance (n = 696) or intermittently (n = 690) until progression, at which point they were switched to continuous ADT.
Median overall survival (OS) reached 9.1 years for the continuous arm versus 8.8 years for the intermittent group (hazard ratio [HR], 1.02), which translated to statistical significance for the noninferiority of the study's intermittent protocol (
P
= .009). At 7 years' follow-up, disease-specific mortality was 18% in the intermittent group compared with 15% in the continuous arm, which Klotz said was not statistically significant (HR, 1.18;
P
= .24).
Castration resistance occurred at a median of 10 years' follow-up for men who received continuous ADT compared with 9.8 years for men in the intermittent arm (HR, 0.80;
P
= .024). The fact that the median duration of OS was shorter than the median time to castration resistance in both groups points to the fact that several men died from causes other than prostate cancer.
The rate of deaths unrelated to prostate cancer was 9% higher in the continuous arm than the intermittent group. Klotz theorized that the known metabolic effects of continuous ADT might account for some of the non-cancer deaths in this group.
In most phase II studies comparing intermittent ADT with continuous ADT, Klotz said men in the intermittent group were on treatment 50% of the time. On average, men randomized to intermittent ADT in Klotz's study were actively treated 27% of the time, spending a median of 15.4 months on an LHRH and 37.6 months off.
At baseline, all the men had nonmetastatic prostate cancer with a PSA level of >3 ng/ml and a serum testosterone level of >5 nmol/L. After randomization and initial flare blockade with an anti-androgen, patients in the intermittent group received an LHRH for 8 months. At that point, treatment stopped for men with normal PSA levels. After 8 months off therapy, those with a PSA level exceeding 10 ng/ml resumed therapy for another 8 months. Men whose PSA level rose above 10 ng/ml within 2 months of treatment discontinuation were switched to continuous therapy.
In each group, a similar proportion of patients experienced the most common adverse events, including erectile dysfunction, loss of libido, incontinence issues, fatigue, myocardial ischemia/infarction, and osteoporotic fracture. Patients in the intermittent ADT arm were significantly less likely to experience hot flashes than patients in the continuous arm, however (90% vs 93%;
P
= .04). Klotz said the investigators are still analyzing the data to assess quality-of-life issues, including off-treatment events.
In the absence of studies to confirm that continuous ADT is associated with more non-cancer deaths than intermittent ADT, neither regimen appears to confer a survival advantage. The primary benefits of administering intermittent androgen suppression appear to be cost savings and less inconvenience for patients. Oliver Sartor, MD, medical director, Tulane Cancer Center, New Orleans, Louisiana, was a discussant at the meeting. He said he already uses intermittent therapy for his patients but monitors them every 2 months.
Related Items
Guidelines on Screening for Breast, Prostate, and Lung Cancers
By
Christin Melton
Web Exclusives
Conference Correspondent
Managing Hyperglycemia in Patients Receiving Steroid Treatment
By
Christin Melton
TON - August 2011 VOL 4, NO 5
Supportive Care
,
Palliative Care
,
Conference Correspondent
Having Evidence-Based Discussions on CAM
By
Christin Melton
TON - June 2011, Vol 4, No 4
Conference Correspondent
Advanced Practice Nurses Forge New Ground in Radiation Oncology Units
By
Christin Melton
Web Exclusives
Conference Correspondent
Changing the Paradigm of Care for Dying Patients
By
Christin Melton
TON - June 2011, Vol 4, No 4
Conference Correspondent
Genotyping: Looking at the Future of Lung Cancer Care
By
Christin Melton
Web Exclusives
Conference Correspondent
Managing Hyperglycemia in Patients Receiving Steroid Treatment
By
Christin Melton
Web Exclusives
Conference Correspondent
A Review of Investigational Drugs at HOPA
By
Christin Melton
Web Exclusives
Drug Updates
Oncology Nurses Best Positioned to Talk to Patients About Lymphedema
By
Christin Melton
Web Exclusives
Conference Correspondent
Preventing Skeletal-Related Events in Patients
By
Christin Melton
Web Exclusives
Conference Correspondent
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Best Practices in Breast Cancer Therapy | OFS
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION